TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).

Sylvia Adams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.